Christopher B. Ehrlich, Director at eFFECTOR Therapeutics, Inc. (EFTR), bought 3,000 shares at $4.45 ($13K) on 2022-02-14, disclosed to the SEC on 2022-02-22.
Open-market purchase of $13k EFTR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.45 | 2,000 | $9K | 67.4% |
| 2 | $4.30 | 1,000 | $4K | 32.6% |
| Total | $4.40 avg | 3,000 | $13K | 100% |
| Filing → |
| EFTR | BUY | 2022-02-10 | $10K | — | Filing → |
| EFTR | BUY | 2022-02-07 | $31K | — | Filing → |
| EFTR | BUY | 2022-01-31 | $27K | — | Filing → |